Work

Rifaximin For Preventing Acute Graft Versus Host Disease: Impact On Plasma Markers Of Inflammation And T Cell Activation

Year: 2010

Type: article

Abstract: Bacterial translocation across damaged gut mucosa is critical in the pathogenesis of acute graft versus host disease (AGVHD). Pre-clinical research has demonstrated that mitigating the effects of gut flora prevents AGVHD. Rifaximin is a broad acting, minimally absorbed oral antibiotic, which has been shown to be effective in inflammatory bowel disease. We conducted a pilot trial to test the hypothesis that rifaximin would abrogate systemic inflammation and resultant T cell activation in allogeneic transplant recipients.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2009.12.457